INNOVADERM
6.7.2021 15:02:10 CEST | Business Wire | Press release
Innovaderm today announced it has been awarded the CRO Leadership Awards. This huge achievement testifies to the excellency and ever-growing presence in the CRO world.
Innovaderm is offering full-service clinical research services, while serving its partners in their journey to discover new dermatology therapies.
Being selected by sponsors as top award winner in the Capabilities category, Innovaderm proves once more being top of mind for drug developers when it comes to selecting a CRO for their phase 1 to 3 with sites in North America and Europe. Other categories where Innovaderm performed in the top are: Expertise, Compatibility, Quality and Reliability.
"These award winners have proven themselves to be the top service providers in each category, said Ed Miseta, chief editor for Clinical Leader. "I congratulate all of them for work ethic they exhibit in consistently meeting the needs of their drug development clients."
The CRO Leadership Awards honours clinical research organizations that meet and exceed customer expectations. For 2021, Clinical Leader and Life Science Leader have once again teamed up with Industry Standard Research (ISR) to determine the winners. Recipients of the awards are vetted against more than 60 CROs and the participants are assessed by sponsor decision makers who have used clinical research services within the past 18 months.
Dr. Robert Bissonnette, Founder and CEO of Innovaderm, commented: “We are very pleased to receive this recognition. It is a tremendous honour to see our work acknowledged by Biotech and Pharma sponsors. At Innovaderm, we pride ourselves in offering niche expertise and quality services and these awards demonstrate that we are able to deliver.”
About Innovaderm
Innovaderm is a full-service contract research organization (CRO) offering support in the management of Phase 1 to 3 trials worldwide. Innovaderm partners with the drug industry to support single and multicenter clinical research & development. For the past 20 years, our team has supported sponsors with their medical, scientific and clinical execution in dermatology trials. To learn more about Innovaderm, please visit us on our website , LinkedIn , or Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210706005089/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Recyclable Packaging and Responsible Water Management: Barilla’s Commitment to a More Sustainable Future23.3.2026 10:30:00 CET | Press release
99.8% of the packaging sold is designed to be recyclable.Over 50% of the materials used in Barilla Group’s packaging are recycled, and 71% are paper-based.+45% water recycled and reused in 2024 compared to 2022, and +164% in water-stressed areas. With 99.8% of the packaging designed to be recyclable and a 45% increase in water recycled and reused in 2024 compared to 2022, Barilla continues to strengthen its commitment to the responsible management of resources. The company is reaffirming this commitment on the occasion of Global Recycling Day (March 18) and World Water Day (March 22), two moments that highlight the importance of increasingly sustainable production models – from efficient water management to the design of more circular packaging solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320294356/en/ Barilla Group's Rubbiano Plant (PR) WATER AS A STRATEGIC RESOURCE TO PROTECT A fundamental resource for past
Massive Gaming Secures MGA B2B License to Expand Global iGaming Partnerships23.3.2026 10:13:00 CET | Press release
Massive Gaming (MVG), a global iGaming content provider with headquarters in Australia, has secured a B2B Gaming License from the Malta Gaming Authority (MGA), marking a key milestone in the company’s expansion into regulated international markets. The MGA license enables Massive Gaming to supply its gaming content and solutions to operators licensed under the Malta regulatory framework, strengthening the company’s ability to collaborate with partners across Europe and other regulated jurisdictions. To support its regulatory expansion, Massive Gaming established MVG Malta, a dedicated entity created as part of the licensing process, and which supports the company’s broader strategy to strengthen its presence within the European iGaming ecosystem. Massive Gaming develops its gaming portfolio across three studios - Slot Mart, Whale House and Blitzcrown. All three deliver a range of gaming experiences spanning traditional slot titles, regulated market content and emerging non-traditional
LTM Expands BlueVerse™ Tech with AppIQ, AgentIQ and FusionIQ to Accelerate AI‑Led Engineering23.3.2026 09:30:00 CET | Press release
LTM – the Business Creativity partner to the world’s largest enterprises, today announced the expansion of BlueVerseTM Tech, its AI‑led engineering platform, with the launch of AppIQ, AgentIQ and FusionIQ—three purpose‑built platforms designed to help enterprises modernize applications, orchestrate AI‑first software delivery, and engineer quality at scale. As software development evolves from human‑only execution to human + intelligent agents, traditional effort‑driven engineering and QA models are increasingly unable to keep pace. These BlueVerseTM platforms embed agentic, engineering‑aware AI across the software development lifecycle (SDLC), enabling enterprises to move faster from legacy complexity to modern, resilient, and high‑quality digital systems. AppIQ — Modernize Legacy Applications, Faster AppIQ applies AI to read and understand legacy codebases, generate documentation, map functional workflows, and produce actionable specifications for forward engineering. What previously
Galderma Receives U.S. FDA Approval for Restylane® Contour™ for the Correction of Temple Hollowing23.3.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Contour* for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support overall facial balance and harmony1-3 The approval is based on clinical data showing Restylane Contour, part of Galderma’s versatile portfolio of hyaluronic acid injectables, delivers natural-looking results lasting for up to 18 months and high patient satisfaction1,2 This follows the recent U.S. FDA approval for Restylane Lyft™ for the enhancement of the chin profile and the debut of the ‘Wake Up to Restylane’ campaign in the U.S., highlighting Galderma’s commitment to continuing to evolve this versatile portfolio to meet emerging and diverse needs, including the desire for effortless, ‘wake‑up‑ready’ beauty4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the U.S. FDA has approved Restylane Contour for the correction of temple hol
Paving the Way for Real‑Time Earth Observation: Space Compass and SWISSto12 Sign Contract for First Commercial GEO Optical Data Relay Satellite23.3.2026 05:00:00 CET | Press release
Space Compass Corporation (“Space Compass”) and SWISSto12 SA (“SWISSto12”) announced today that they have executed a procurement contract for the first GEO optical data relay satellite. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260320584108/en/ (From Left to Right): Julie Pignon, Legal Counsel, SWISSto12; 倉田 るり子 (Ruriko Kurata), Legal Counsel, Space Compass; 小松 大実 (Hiromi Komatsu), Co-CEO, Space Compass; 田中 良太 (Ryota Tanaka), Engineering Director, Space Compass; Emile de Rijk, CEO, SWISSto12; Fredrik Gustavsson, Chief Financial and Strategy Officer, SWISSto12. This agreement represents a major milestone toward the realization of Space Compass’s optical data relay service. With high-speed, high-capacity optical data relay service, Space Compass aims to transform Earth Observation from just a tracking record into a real-time decision-making tool. For SWISSto12, the contract represents further validation of the company’s a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom